CGON
CG Oncology Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +12.8% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 7.01K | $443,642 | n/a | n/a |
| Q2 2026 | 94 | +7 | 45.65M | $3.24B | +12 | −5 |
| Q1 2026 | 90 | +11 | 42.64M | $2.85B | +15 | −4 |
| Q4 2025 | 77 | 0 | 47.85M | $1.99B | n/a | n/a |
| Q3 2025 | 16 | 0 | 30.32M | $1.22B | +1 | −1 |
| Q2 2025 | 13 | +1 | 24.41M | $634.75M | +2 | −1 |
| Q1 2025 | 9 | 0 | 12.23M | $299.43M | +1 | −1 |
| Q4 2024 | 9 | +1 | 9.32M | $267.32M | +1 | n/a |
| Q3 2024 | 7 | -2 | 3.66M | $137.92M | n/a | −2 |
| Q2 2024 | 9 | n/a | 2.48M | $78.32M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 6.58M | +11.4% | $264.93M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 2 | Wellington Management ✦ | 5.51M | +190.3% | $222.05M | 0.0% | ▲ Add | 6 | SEC ↗ ×7 |
| 3 | BlackRock ✦ (passive) | 4.59M | +2.9% | $184.74M | 0.0% | ▲ Add | 2 | SEC ↗ ×11 |
| 4 | Fidelity (FMR) ✦ | 3.87M | +0.2% | $155.71M | 0.0% | ▲ Add | 2 | SEC ↗ ×4 |
| 5 | State Street Global Advisors ✦ (passive) | 2.05M | -5.5% | $82.44M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 6 | T. Rowe Price ✦ | 1.59M | -21.1% | $64.00M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 7 | Point72 Asset Management ✦ | 1.52M | +3.3% | $61.36M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 8 | Geode Capital Management ✦ (passive) | 1.47M | +10.3% | $59.35M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 9 | Goldman Sachs Group ✦ | 1.37M | n/a | $55.06M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 10 | Morgan Stanley ✦ | 642.41K | n/a | $25.88M | 0.0% | n/c | 1 | SEC ↗ ×7 |
| 11 | JPMorgan Chase ✦ | 455.76K | n/a | $18.36M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 12 | Millennium Management ✦ | 253.18K | -73.6% | $10.20M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 13 | Citadel Advisors ✦ | 238.77K | +36.2% | $9.62M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 112.27K | -0.7% | $4.52M | 0.0% | ▼ Trim | 3 | SEC ↗ ×4 |
| 15 | Marshall Wace ✦ | 56.38K | New | $2.27M | 0.0% | New | 1 | SEC ↗ |
| 16 | D. E. Shaw & Co. ✦ | 22.61K | +115.4% | $910,932 | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $2.27M | 0.0% |
Exited
| Renaissance Technologies | $1.20M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 232 holders, 86.28M shares, $5.07B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 500 sh · $30,825
Director · 500 sh · $31,240
Director · 1.00K sh · $72,980
Director · 1.00K sh · $74,540
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology